

# Ubiquilin 4 Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP20424a

## **Product Information**

Application	WB, E
Primary Accession	<u>Q9NRR5</u>
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB43631
Calculated MW	63853
Antigen Region	1-30

### **Additional Information**

Gene ID	56893
Other Names	Ubiquilin-4, Ataxin-1 interacting ubiquitin-like protein, A1Up, Ataxin-1 ubiquitin-like-interacting protein A1U, Connexin43-interacting protein of 75 kDa, CIP75, UBQLN4, C1orf6, CIP75, UBIN
Target/Specificity	This Ubiquilin 4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human Ubiquilin 4.
Dilution	WB~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	Ubiquilin 4 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

#### **Protein Information**

Name	UBQLN4 {ECO:0000303 PubMed:27113755, ECO:0000312 HGNC:HGNC:1237}
Function	Regulator of protein degradation that mediates the proteasomal targeting of misfolded, mislocalized or accumulated proteins (PubMed: <u>15280365</u> ,

	PubMed:27113755, PubMed:29666234, PubMed:30612738). Acts by binding polyubiquitin chains of target proteins via its UBA domain and by interacting with subunits of the proteasome via its ubiquitin-like domain (PubMed:15280365, PubMed:27113755, PubMed:30612738). Key regulator of DNA repair that represses homologous recombination repair: in response to DNA damage, recruited to sites of DNA damage following phosphorylation by ATM and acts by binding and removing ubiquitinated MRE11 from damaged chromatin, leading to MRE11 degradation by the proteasome (PubMed:30612738). MRE11 degradation prevents homologous recombination repair, redirecting double-strand break repair toward non-homologous end joining (NHEJ) (PubMed:30612738). Specifically recognizes and binds mislocalized transmembrane-containing proteins and targets them to proteasomal degradation (PubMed:27113755). Collaborates with DESI1/POST in the export of ubiquitinated proteins from the nucleus to the cytoplasm (PubMed:29666234). Also plays a role in the regulation of the proteasomal degradation of non-ubiquitinated GJA1 (By similarity). Acts as an adapter protein that recruits UBQLN1 to the autophagy machinery (PubMed:23459205). Mediates the association of UBQLN1 with autophagosomes and the autophagy-related protein LC3 (MAP1LC3A/B/C) and may assist in the maturation of autophagosomes to autolysosomes by mediating autophagosome-lysosome fusion (PubMed:23459205).
Cellular Location	Nucleus. Cytoplasm. Chromosome Endoplasmic reticulum {ECO:0000250 UniProtKB:Q99NB8}. Cytoplasm, perinuclear region {ECO:0000250 UniProtKB:Q99NB8}. Cytoplasmic vesicle, autophagosome. Note=Colocalizes with the proteasome, both in nucleus and cytoplasm (PubMed:15280365). Exported from the nucleus following interaction with DESI1/POST (PubMed:29666234). In response to DNA damage and phosphorylation at Ser-318 by ATM, localizes to the nucleus and is recruited to sites of DNA damage (PubMed:30612738).
Tissue Location	Highly expressed in pancreas, kidney, skeletal muscle, heart and throughout the brain, and at lower levels in placenta, lung and liver.

## Background

Plays a role in the regulation of proteasomal protein degradation. Depending on the case, may promote or inhibit proteasomal protein degradation.

#### Images



Ubiquilin 4 Antibody (N-term) (Cat. #AP20424a) western blot analysis in 293 cell line lysates (35ug/lane).This demonstrates the Ubiquilin 4 antibody detected the Ubiquilin 4 protein (arrow).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.